公告称，本次启动的国家科技重大专项，聚焦ICAS相关认知障碍的诊疗难题，依托多学科交叉优势开 展系统性研究，核心方向包括建立ICAS相关认知障碍的评估技术体系及深度推理预测大模型，以提供 疾病早期筛查、风险预判和预防、干预的诊疗工具，并建立ICAS相关认知障碍全场景闭环管理体系。 本文源自：智通财经网 本项目已于近期正式启动。同时，智精灵科技与首都医科大学宣武医院(宣武医院)等联合申报的"认知 障碍数字医疗北京市重点实验室"亦已于近日正式获批成立。 智通财经获悉，脑动极光-B(06681)涨超5%，截至发稿，涨5.09%，报6.18港元，成交额1666.49万港 元。 消息面上，12月22日，脑动极光-B发布公告，公司旗下全资附属公司北京智精灵科技有限公司(智精灵 科技)作为重要合作单位，共同参与国家科技重大专项"癌症、心脑血管、呼吸和代谢性疾病防治研 究"项目，课题名称为《基于深度推理大模型的颅内动脉粥样硬化狭窄相关认知障碍数字诊疗关键技术 建立及场景化应用》(国家科技重大专项)。 ...

Core Viewpoint - Brainstorm Aurora-B (06681) has seen a stock price increase of over 5%, currently trading at 6.18 HKD with a transaction volume of 16.66 million HKD, following the announcement of its participation in a significant national technology project focused on the prevention and treatment of various diseases, including cognitive disorders related to intracranial atherosclerosis [1] Group 1: Company Developments - The company announced that its wholly-owned subsidiary, Beijing Zhijingling Technology Co., Ltd. (Zhijingling Technology), is a key partner in the national technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The project, which has recently been officially launched, aims to address diagnostic challenges related to cognitive disorders associated with intracranial atherosclerosis (ICAS) [1] - Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has also successfully established the "Beijing Key Laboratory of Digital Medical for Cognitive Disorders" [1] Group 2: Project Focus and Objectives - The national technology major project focuses on the diagnostic challenges of ICAS-related cognitive disorders, leveraging interdisciplinary advantages for systematic research [1] - Key objectives include the establishment of an assessment technology system for ICAS-related cognitive disorders and the development of a deep reasoning predictive model to provide early screening, risk assessment, prevention, and intervention tools [1] - The project aims to create a comprehensive management system for ICAS-related cognitive disorders, ensuring a closed-loop management approach across various scenarios [1]

Core Viewpoint - Brain Dynamics Aurora-B (06681) has announced its participation in a significant national science and technology project focused on the prevention and treatment of diseases such as cancer, cardiovascular, respiratory, and metabolic diseases, specifically targeting cognitive disorders related to intracranial atherosclerosis [2][5]. Group 1 - The company's stock price increased by 6.62%, currently trading at 6.28 HKD with a transaction volume of 34.81 million HKD [2][5]. - The project, titled "Establishment of Key Technologies for Digital Diagnosis and Treatment of Cognitive Disorders Related to Intracranial Atherosclerosis," has officially commenced [2][5]. - The project aims to develop a comprehensive assessment technology system and deep reasoning predictive model for cognitive disorders associated with intracranial atherosclerosis, providing tools for early disease screening, risk assessment, prevention, and intervention [2][5]. Group 2 - The establishment of the "Beijing Key Laboratory for Digital Medical Treatment of Cognitive Disorders," in collaboration with Capital Medical University Xuanwu Hospital, has also been officially approved [2][5]. - The project leverages interdisciplinary advantages to conduct systematic research on the diagnostic challenges of cognitive disorders related to ICAS [2][5]. - The initiative will create a closed-loop management system for cognitive disorders associated with ICAS [2][5].

Core Viewpoint - The company, through its subsidiary Beijing Zhijingling Technology Co., Ltd., is participating in a national major science and technology project focused on the diagnosis and treatment of cognitive disorders related to intracranial atherosclerotic stenosis (ICAS) [1][2][3] Group 1: Project Overview - The national major science and technology project aims to address the diagnostic challenges of ICAS-related cognitive disorders by developing a comprehensive assessment technology system and deep reasoning predictive models [2] - The project is led by Xuanwu Hospital and involves collaboration with several prestigious institutions, including the Chinese Academy of Medical Sciences and Jilin University, bringing together top experts from neurology, cognitive neuroscience, psychology, and artificial intelligence [2][3] Group 2: Company Role and Contributions - The company will leverage its expertise in digital diagnosis and treatment of neurological and psychiatric disorders to develop deep reasoning models and digital treatment platforms for ICAS-related cognitive disorders [3] - The newly established Beijing Key Laboratory for Digital Therapy of Cognitive Disorders will integrate clinical medicine, basic research, technology development, and hardware innovation, with the company playing a central role in algorithm development and user experience optimization [3]

Core Viewpoint - The company, through its subsidiary Beijing Zhijingling Technology Co., Ltd., is participating in a national major science and technology project focused on the diagnosis and treatment of cognitive disorders related to intracranial atherosclerotic stenosis (ICAS) [1][2][3] Group 1: Project Overview - The national major science and technology project aims to address the diagnostic challenges of ICAS-related cognitive disorders by developing a comprehensive assessment technology system and deep reasoning predictive models [2] - The project is led by Xuanwu Hospital and involves collaboration with several prestigious institutions, including the Chinese Academy of Medical Sciences and Jilin University, bringing together top experts from neurology, cognitive neuroscience, psychology, and artificial intelligence [2][3] Group 2: Company Role and Contributions - The company will leverage its expertise in digital diagnosis and treatment of neurological and psychiatric disorders to develop deep reasoning models and digital treatment platforms for ICAS-related cognitive disorders [3] - The newly established Beijing Key Laboratory for Digital Therapy of Cognitive Disorders will integrate clinical medicine, basic research, technology development, and hardware innovation, with the company playing a key role in algorithm development and user experience optimization [3]

Core Viewpoint - The company, Brainstorm Aurora-B (06681.HK), has announced its participation in a significant national science and technology project focused on the prevention and treatment of major diseases, highlighting its leadership in digital diagnosis for cognitive disorders [1] Group 1: Project Involvement - The company's wholly-owned subsidiary, Beijing Zhijingspirit Technology Co., Ltd., is a key collaborator in the national science and technology major project titled "Research on the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases" [1] - The specific project under this initiative is named "Establishment of Key Technologies for Digital Diagnosis Related to Intracranial Atherosclerotic Stenosis and Cognitive Disorders Based on Deep Reasoning Large Models" with project number 2025ZD0546200 [1] Group 2: Laboratory Establishment - Zhijingspirit Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has successfully applied for the establishment of the "Beijing Key Laboratory for Digital Medical Treatment of Cognitive Disorders," which has recently been approved [1] - The approval of the key laboratory further emphasizes the company's technological leadership in the field of digital diagnosis for cognitive disorders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 本次啟動的國家科技重大專項，聚焦ICAS相關認知障礙的診療難題，依託多 學科交叉優勢開展系統性研究，核心方向包括建立ICAS相關認知障礙的評估 技術體系及深度推理預測大模型，以提供疾病早期篩查、風險預判和預防、 干預的診療工具，並建立ICAS相關認知障礙全場景閉環管理體系。 本項目的實施旨在建立國際領先的ICAS相關認知障礙診療技術體系，構建符 合中國國情的疾病管理模式，有效預防與延緩疾病進展，助力「健康中國」戰 略。本項目由宣武醫院牽頭，聯合中國醫學科學院北京協和醫院、中國科學 院心理研究所、吉林大學、北京師範大學及智精靈科技等單位共同攻關。研 究團隊匯集了神經病學、認知神經科學、心理學與人工智能等領域的頂尖專 家，並與國際領先研究團隊保持長 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by recent developments in regulatory support and technological advancements [1]. Group 1: Stock Performance - Nanjing Panda (00553) increased by 4.16%, reaching HKD 4.51 [1] - MicroPort NeuroTech (02172) rose by 4.24%, trading at HKD 10.83 [1] - BrainCo (06681) saw a 2.58% increase, priced at HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for innovative regulatory methods, the establishment of standard systems, and enhanced technical guidance [1] Group 3: Industry Outlook - According to Guotai Junan, the BCI industry is poised for significant growth due to technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a promising market outlook [1]

Core Viewpoint - The Hong Kong stock market is experiencing a surge in brain-computer interface concept stocks, indicating growing investor interest in this sector [1] Group 1: Stock Performance - Nanjing Panda (00553.HK) increased by 4.16%, reaching HKD 4.51 [1] - Weikang Brain Science (02172.HK) rose by 4.24%, trading at HKD 10.83 [1] - Brain Motion Aurora-B (06681.HK) saw a gain of 2.58%, priced at HKD 5.96 [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by government support and technological advancements, indicating a promising market outlook for the industry [1] Group 1: Stock Performance - Nanjing Panda (600775) shares increased by 4.16%, reaching HKD 4.51 [1] - Microwin Brain Science (02172) shares rose by 4.24%, reaching HKD 10.83 [1] - Brain Motion Aurora-B (06681) shares grew by 2.58%, reaching HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for enhanced cross-departmental collaboration to address key technical challenges and improve the industry supply chain [1] Group 3: Market Outlook - According to Guotai Junan, the BCI industry is expected to benefit from technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a positive market outlook [1]